Microba’s MetaXplore™ Test Shows Promising Results in GI Disorder Management

Microba Life Sciences Limited ( (AU:MAP) ) just unveiled an announcement.

Microba Life Sciences Limited has announced preliminary results from a study involving over 4,600 patients using its MetaXplore™ GI Plus test. The study found that 71.4% of the reports identified actionable results, with a significant portion showing abnormal microbiome markers linked to gastrointestinal health. The findings suggest that the MetaXplore test can significantly aid clinicians in diagnosing and managing chronic lower gastrointestinal disorders. Additionally, a separate survey indicated that 65.5% of patients reported health improvements after following clinician-directed recommendations based on the test results. This highlights the potential of MetaXplore to reshape clinical management and improve outcomes for patients with these conditions, addressing an estimated addressable market of over 82 million patients across several countries.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

More about Microba Life Sciences Limited

Microba Life Sciences Limited is a precision microbiome company that focuses on the assessment and management of gastrointestinal disorders. The company offers the MetaXplore™ GI Plus test, which helps in identifying underlying gut issues to improve patient outcomes.

Average Trading Volume: 190,637

Technical Sentiment Signal: Sell

Current Market Cap: A$78.37M

See more insights into MAP stock on TipRanks’ Stock Analysis page.